Puspita Febriana M, Yunir Em, Agustina Putri S, Sauriasari Rani
Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Diabetes Metab Syndr Obes. 2021 Sep 7;14:3841-3849. doi: 10.2147/DMSO.S310091. eCollection 2021.
National formulary restrictions in Indonesia (2019) require estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m to be able to prescribe telmisartan and valsartan and ACE-I intolerance to be able to prescribe irbesartan and candesartan. These restrictions are based on economic considerations and differ from American Diabetes Association (ADA) (2020) guidelines which allow equal use of angiotensin II receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACE-I) without restriction. Since there is a need to evaluate the different effects of ACE-I and ARB in the Indonesian hypertensive type 2 diabetes mellitus (T2DM) population, we compare their effects on urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and blood potassium level.
A prospective cohort study at RSUPN Dr. Cipto Mangunkusumo Hospital was conducted in 123 T2DM patients. We followed the study subjects prospectively for three months using a validated questionnaire, health record, and laboratory data.
After 3 months of observation, there were no significant changes, except increased BMI values (p = 0.046) in the ACE-I group, and decreased LDL value (p = 0.016) and HDL value (p = 0.004) in the ARB group. Multivariate analysis showed that the consumption of ACE-I or ARB was not associated with a decrease/constant of UACR or increase potassium level, even after adjusting by confounding variables. Interestingly, we found ARB was more likely to increase eGFR, but the significance was lost once the duration of ACE-I/ARB use was entered into the model. In addition, BMI >25 kg/m was a significant factor associated with decreased/constant UACR, maleness was significant for increased eGFR, and declining systolic blood pressure for increase in potassium level.
ACE-I and ARB have a similar effect on UACR and blood potassium level, but ARB slightly increased eGFR compared to ACE-I within three months of consumption.
印度尼西亚(2019年)的国家药品目录限制规定,估算肾小球滤过率(eGFR)低于60 mL/min/1.73 m²时才能开具替米沙坦和缬沙坦,对ACE-I不耐受时才能开具厄贝沙坦和坎地沙坦。这些限制基于经济考量,与美国糖尿病协会(ADA)(2020年)的指南不同,后者允许无限制地平等使用血管紧张素II受体阻滞剂(ARB)和血管紧张素转换酶抑制剂(ACE-I)。由于有必要评估ACE-I和ARB在印度尼西亚2型糖尿病(T2DM)高血压患者人群中的不同作用,我们比较了它们对尿白蛋白与肌酐比值(UACR)、估算肾小球滤过率(eGFR)和血钾水平的影响。
在西托·曼古库苏莫博士国家综合医院对123例T2DM患者进行了一项前瞻性队列研究。我们使用经过验证的问卷、健康记录和实验室数据对研究对象进行了为期三个月的前瞻性随访。
经过3个月的观察,除ACE-I组的BMI值升高(p = 0.046),ARB组的低密度脂蛋白值降低(p = 0.016)和高密度脂蛋白值降低(p = 0.004)外,没有显著变化。多变量分析表明,即使在对混杂变量进行调整后,使用ACE-I或ARB与UACR降低/稳定或血钾水平升高无关。有趣的是,我们发现ARB更有可能增加eGFR,但一旦将ACE-I/ARB的使用时长纳入模型,这种显著性就消失了。此外,BMI>25 kg/m²是与UACR降低/稳定相关的显著因素,男性对eGFR升高有显著影响,收缩压下降对血钾水平升高有显著影响。
ACE-I和ARB对UACR和血钾水平有相似的作用,但在服用三个月内,与ACE-I相比,ARB使eGFR略有升高。